Julius Chapiro: Minimally Invasive Liver Cancer Treatment

Release Date:

Howie and Harlan are joined by Julius Chapiro to discuss advances in the use of machine learning and molecular imaging to understand and treat liver cancer and his work as the director of Yale’s Center for Minimally Invasive Therapies. Harlan reports on a medical journal paper that highlights positive outcomes while ignoring negative ones; Howie warns of the impact of private equity ownership of medical practices. Links: “MR Imaging Biomarkers for the Prediction of Outcome after Radiofrequency Ablation of Hepatocellular Carcinoma: Qualitative and Quantitative Assessments of the Liver Imaging Reporting and Data System and Radiomic Features” “Froedtert & the Medical College of Wisconsin - Liver Cancer Minimally Invasive Therapies” ”Predicting tumor recurrence on baseline MR imaging in patients with early-stage hepatocellular carcinoma using deep machine learning” “Comparison of Existing Response Criteria in Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization Using a 3D Quantitative Approach” “Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients” “Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients” “Monetizing Medicine: Private Equity And Competition In Physician Practice Markets” Learn more about the MBA for Executives program at Yale SOM. Email Howie and Harlan comments or questions.

Julius Chapiro: Minimally Invasive Liver Cancer Treatment

Title
Julius Chapiro: Minimally Invasive Liver Cancer Treatment
Copyright
Release Date

flashback